BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/11/2021 9:22:17 AM | Browse: 813 | Download: 1526
Publication Name World Journal of Clinical Cases
Manuscript ID 63277
Country Taiwan
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine
Manuscript Source Unsolicited Manuscript
All Author List Chung-Tsui Huang and Yao-Jen Liang
ORCID
Author(s) ORCID Number
Chung-Tsui Huang http://orcid.org/0000-0002-2051-0134
Yao-Jen Liang http://orcid.org/0000-0001-5036-9592
Funding Agency and Grant Number
Corresponding Author Yao-Jen Liang, PhD, Professor, Graduate Institute of Applied Science and Engineering, Department and Institute of Life Science, Fu-Jen University, No. 510 Zhongzheng Road, Xinzhuang District, New Taipei 242, Taiwan. 071558@mail.fju.edu.tw
Key Words Statin; Pancreatic cancer; Precision medicine; Anti-tumor; Pancreatic adenocarcinoma
Core Tip Statin is a cholesterol-lowering agent through the inhibition of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase and subsequently reduction of cholesterol precursor, firstly commercial use in 1987. This is a mini-review for statin and pancreatic adenocarcinoma, focusing on the therapeutic effect. The method was using literature searches and literature summarized from 1992 to 2021. The effect of microbiota on the tumor microenvironment of pancreatic adenocarcinoma is a new therapeutic approach when statin can modulate the gut microbiota.
Publish Date 2021-06-11 09:22
Citation Huang CT, Liang YJ. Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine (review). World J Clin Cases 2021; 9(18): 4500-4505
URL https://www.wjgnet.com/2307-8960/full/v9/i18/4500.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i18.4500
Full Article (PDF) WJCC-9-4500.pdf
Full Article (Word) WJCC-9-4500.docx